Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

Phase 3

Completed

• Conditions: COVID-19
• Interventions: Drug: Standard of care; Drug: Favipiravir

• Registration Number: NCT04542694
• Lead Sponsor: Promomed, LLC

Brief Summary

This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Detailed Description

Upon signing the informed consent form and screening, 200 eligible patients with polymerase chain reaction (PCR) confirmed COVID-19 are randomized at a 1:1 ratio to receive either Favipiravir 1600 mg twice a day (BID) on Day 1 followed by 600 mg BID on Days 2-14 (1600/600 mg), or SOC. The course of treatment by Favipiravir is 14 days.

Study Timeline

• Study Start: 2020-05-21
• Primary Completion: 2020-08-10
• Study Completion: 2020-08-20
• Study First Submitted: 2020-09-04
• Study First Submitted QC: 2020-09-04
• Study First Posted: 2020-09-09
• Results First Submitted: 2020-10-11
• Status Verified: 2020-11
• Results First Submitted QC: 2020-11-03
• Last Update Submitted: 2020-11-03
• Results First Posted: 2020-11-05
• Last Update Posted: 2020-11-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Signing and dating of the Informed Consent Form of the Patient Information Leaflet (PIL) by patients.

2. Men and women aged 18 to 80 years inclusive at the time of signing the Informed Consent Form in PIL.

3. No difficulty with oral medication (e.g. swallowing disorder).

4. Patient diagnosed with "Coronavirus infection caused by SARS-CoV-2 (confirmed)1, moderate severity form*" established in accordance with the Interim Guidelines of the Russian Ministry of Health for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), (revision 6 of 28.04.2020).

   *Moderate severity form: fever above 38 °C, BR above 22/min, dyspnea during exercise, pneumonia (confirmed by lung CT), SpO2 < 95%, C reactive protein (CRP) serum level above 10 mg/l.

5. Patient should be hospitalized no more than 48 hours before the start of the study therapy.

6. Positive PCR result for presence of SARS-CoV-2 RNA at screening phase (results obtained within 7 days prior to screening are appropriate).

7. Patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. Persons eligible for participation in the study: - Women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). Women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.

Exclusion Criteria

1. Hypersensitivity to favipiravir and/or other components of the study drug.
2. Impossibility of CT procedure (for example, gypsum dressing or metal structures in the field of imaging).
3. The need to use drugs from the list of prohibited therapy.
4. Need for treatment in the intensive care unit.
5. Impaired liver function (AST and/or ALT ≥ 2 UNL and/or total bilirubin ≥ 1.5 UNL) at the time of screening.
6. Impaired kidney function (creatinine clearance according to Cockcroft-Gault formula less than 45 ml/min) at the time of screening.
7. Positive testing for HIV, syphilis, hepatitis B and/or C.
8. Chronic heart failure FC III-IV according to New York Heart Association (NYHA) functional classification.
9. Malabsorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others).
10. Malignancies in the past medical history.
11. Alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening.
12. Schizophrenia, schizoaffective disorder, bipolar disorder, or other history of mental pathology or suspicion of their presence at the time of screening.
13. Severe, decompensated or unstable somatic diseases (any disease or condition that threaten the patient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study).
14. Any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study.
15. Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of physician investigator).
16. Pregnant or nursing women or women planning pregnancy.
17. Participation in another clinical study for 3 months prior to inclusion in the study.
18. Other conditions that, according to the physician investigator, prevent the patient from being included in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard of care	Standard of care	Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes. Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime.
Favipiravir (Areplivir)	Favipiravir	Arm 1 (n=100) receives the study drug Areplivir film-coated tablets: on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.

Primary Outcome Measures

Name	Time	Method
Rate of Clinical Status Improvement	By Visit 3, approximately 10 days	Rate of clinical status improvement by categorical ordinal scale of clinical status improvement by 2 or more categories by Day 10 WHO Ordinal Scale for Clinical Improvement (WHO-OSCI), 0 - uninfected (There are no clinical and virological signs of infection), 8 - dead, higher scores mean a worse outcome
Time to Clinical Improvement	28 days	Time (in days) to improvement in clinical status by WHO categorical ordinal scale of clinical status improvement.

Secondary Outcome Measures

Name	Time	Method
Rate of Transfer to the Intensive Care Unit	28 Days	Percentage of patients transferred to intensive care unit (% of patients).
Rate of the Use of Mechanical Ventilation	28 Days	Percentage of cases with mechanical lung ventilation (% of patients)
Time Before the End of Fever	28 days	Time (in days) before the end of fever (body temperature \< 37.2 ° C for 3 consecutive days without antipyretic medication).
Rate of the Use of Non-invasive Lung Ventilation	28 Days	Percentage of cases with non-invasive lung ventilation (% of patients).
Rate of Viral Elimination by Day 10	10 days	Percentage of patients with elimination (clearance) of COVID-19 according to PCR data by day 10 (negative PCR results).
Change in the Level of Lung Damage According to CT	Days 15, 21, 28	Assessment of lung injury (degree of damage by "empirical" visual scale and % of patients) according to CT data comparing to baseline. The number of patients in whom by the end of therapy there was an improvement in the condition of the lungs (a decrease in the volume of the lesion according to CT)
Mortality	28 Days	Incidence of fatal cases (% of patients)

Trial Locations

Locations (5)

City Hospital N40 of Kurortny District; 🇷🇺 Saint Petersburg, Russian Federation

Regional Clinic Hospital of Ryazan; 🇷🇺 Ryazan', Russian Federation

Smolensk clinical hospital №1; 🇷🇺 Smolensk, Russian Federation

State Clinical Hospital №50; 🇷🇺 Moscow, Russian Federation

Medical institute Ogarev Mordovia State university; 🇷🇺 Saransk, Russian Federation